Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHPA appointment

This article was originally published in The Tan Sheet

Executive Summary

Heinz Schneider, MD, will assume his new role as VP-Regulatory & Scientific Affairs July 1, the Consumer Healthcare Products Association announces May 5. Schneider most recently served as head of international regulatory affairs at Boots Healthcare International from 2004-2006, and was named global director of regulatory, safety and environment after BHI was acquired by Reckitt Benckiser in October. He takes the place of Doug Bierer, who left CHPA in July (1"The Tan Sheet" July 25, 2005, In Brief)...

You may also be interested in...



People In Brief

CHPA scientists Schneider, Roehrig exit

CHPA’s Bierer

Douglas Bierer, PhD, is resigning from his post as VP - Regulatory & Scientific Affairs for personal reasons, the Consumer Healthcare Products Association announces July 22. "I've enjoyed my time with CHPA and have high hopes for where the Association is going," Bierer said, though he admits "the weekly commute between CHPA's offices in D.C. and my family in Ohio has been difficult." Bierer has worked in the OTC industry for nearly 30 years and plans to remain involved with the association following his departure July 28. Lorna Totman, PhD, senior director, scientific affairs & toxicology, will serve as acting VP of the department until Bierer's permanent replacement is hired...

EMA Re-Examines Decisions On Prestige’s Trastuzumab And Synchron Studies

Following decisions by the EMA’s CHMP to deny Prestige Biopharma a marketing authorization for its trastuzumab biosimilar and to suspend the marketing authorizations of dozens of generics due to concerns over bioequivalence tests, the European regulator has confirmed it will review the opinions.

Topics

Latest News
UsernamePublicRestriction

Register

PS099342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel